Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 1,159.77 |
Low | 1,159.77 |
Bid | -- |
Offer | -- |
Previous close | 1,601.59 |
Average volume | 0.00 |
---|---|
Shares outstanding | 51.42m |
Free float | 48.20m |
P/E (TTM) | -- |
Market cap | 4.37bn USD |
EPS (TTM) | -2.06 USD |
Data delayed at least 20 minutes, as of Sep 19 2024.
More ▼
- PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
- PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
- PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
- PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
- PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
- PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
- PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
- Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
- PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
More ▼